This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : IQVIA Holdings Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM
Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024 CI
Stifel Adjusts Price Target on IQVIA Holdings to $288 From $294 MT
UBS Adjusts Price Target on IQVIA Holdings to $295 From $300, Maintains Buy Rating MT
Deutsche Bank Adjusts Price Target on IQVIA Holdings to $275 From $280 MT
Jefferies Adjusts Price Target on IQVIA to $266 From $281 MT
Morgan Stanley Adjusts Price Target on IQVIA to $270 From $275 MT
Truist Adjusts IQVIA Holdings' Price Target to $292 From $297, Keeps Buy Rating MT
Baird Adjusts Price Target on IQVIA to $245 From $254 MT
Leerink Partners Adjusts Price Target on IQVIA to $278 From $290 MT
Evercore ISI Adjusts Price Target on IQVIA to $250 From $275 MT
IQVIA trims full-year revenue forecast on stronger dollar RE
Transcript : IQVIA Holdings Inc., Q1 2024 Earnings Call, May 02, 2024
IQVIA Holdings Q1 Adjusted Earnings, Revenue Increase MT
Earnings Flash (IQV) IQVIA HOLDINGS Reports Q1 Revenue $3.74B, vs. Street Est of $3.71B MT
Earnings Flash (IQV) IQVIA HOLDINGS Reports Q1 EPS $2.54, vs. Street Est of $2.48 MT
IQVIA Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Market Share of Celltrion’s Remsima Rises to 74% in Europe MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1 MT
Mizuho Securities Adjusts IQVIA Holdings' Price Target to $277 From $268, Maintains Buy Rating MT
Declaration of Voting Results by IQVIA Holdings CI
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US MT
Iqvia, Salesforce Collaborate to Accelerate Life Sciences Cloud Development MT
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud CI
Chart Iqvia Holdings Inc.
More charts
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
229.6 USD
Average target price
271.4 USD
Spread / Average Target
+18.22%
Consensus
  1. Stock Market
  2. Equities
  3. IQV Stock
  4. News Iqvia Holdings Inc.
  5. Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US